Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

FACCT Trial
 
NCT04392973
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
125/129 inconclusive
  • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern
  • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
HC-nCoV (Shanghai)
 
NCT04261517
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
15/15 inconclusive
    Kamran
     
    NCT04491994
    RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
    360/180 inconclusive
    • inconclusive 5 % decrease in clinical deterioration (PE) but with a low degree of certainty due to high risk of bias
    NCT04333654
     
    NCT04333654
    RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
    -/- inconclusive
      Zhaowei Chen
       
      ChiCTR2000029559
      RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
      31/31 inconclusive
        Zhaowei Chen
         
        ChiCTR2000029559
        RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
        31/31 suggested
        • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
        • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
        1 study excluded by filtering options (0 RCT / 1 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).